DD-03

N/A

Report date: 2022/04/13 10:28:50
NME

Base Information

Drug NameDD-03
Drug Alias NameDD-03
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsGlucagon receptor agonistsGlucose-Dependent Insulinotropic Polypeptide Receptor agonists
TargetsGlucagon-like peptide 1 receptorGlucagon receptorGlucose-Dependent Insulinotropic Polypeptide Receptor
Therapy Area/IndicationsObesityMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesD&D Pharmatech
China Registration ClassN/A

Develop Information

Active CompaniesMetsera IncD&D Pharmatech
Inactive CompaniesN/A
Active IndicationsObesityMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A